Ewing Sarcoma Drugs Market: By Tumour Type (Bone Tumour, Peripheral Primitive Neuroectodermal Tumour, Askin Tumour, Soft Tissue Tumour), By Drug Type (Vincristine, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Dactinomycin), By Application (Chemotherapy, Surgery, Radiation therapy, Immuno-therapy and Others), By End User (Hospital and Clinics, Cancer Treating Centres and Others) And Geography

Ewing Sarcoma Drugs Market size was valued at USD 286.3 million in 2023 and is poised to grow at a CAGR of 5.6% from 2024-2030. Ewing Sarcoma is a rare type of cancer that occurs in bones or the soft tissue around the bones. It primarily affects children and young adults, with the majority of cases diagnosed in adolescents during their second decade of life. Commonly affects long bones such as the femur, tibia, and humerus, as well as the pelvis. The desire for new and improved medications is fueled by the high death rate, even though a rare disease the increasing prevalence of incidence rates, increasing investments from both government and private research institutions, and growing healthcare expenditure are driving the market expansion. Emerging new therapeutic approaches Personalised medicine, immunotherapies, and targeted therapeutics are changing how Ewing sarcoma is treated. The number of incidences of Ewing Sarcoma is around 1200 for the year 2023 globally, thus owing to the fewer number of patients the expansion of Ewing sarcoma market is not considered as the main priority of companies. It can be expensive to develop medications for uncommon illnesses like Ewing sarcoma. Due to the small market, the prospective return on investment may be unknown, and the costs of research, clinical trials, and regulatory approval are considerably high compared to other markets.

Regulatory standards for drug approval are time-consuming for uncommon diseases with tiny patient groups. Moreover, development of targeted therapies for Ewing sarcoma is a key opportunity for the market players. For instance, Gradalis is developing and testing Vigil, a fully personalized, patient-specific cancer immunotherapy that can be applied to virtually any cancer. Vigil utilizes the patient’s own cancer cells to create a fully personalized cancer immunotherapy. In addition, Oncternal Therapeutics ONCT-216 (formerly called TK216) is a first-in-class small molecule inhibiting the biological activity of the ETS family. It is currently being evaluated in the Phase II portion of a study in patients with relapsed or refractory Ewing sarcoma.

Ewing Sarcoma Drugs Market Key Developments:

• In July 2023, GlaxoSmithKline plc publicised that the Niraparib drug was under clinical development and is currently in Phase II for Ewing Sarcoma and is formulated as hard gelatin capsules, tablets, and film-coated tablets for oral administration.
• In April 2023, Sumitomo Pharma Oncology, Inc. announced that TP-1287, an investigational oral drug CDK9 inhibitor, has received orphan drug designation from the FDA for the treatment of patients with Ewing sarcoma.
• In April 2022, AI Therapeutics announced the acquisition of Entre Chem’s, investigational drug candidate EC-8042 (redesignated AIT-102), a novel targeted cancer therapy in development for cancers including pediatric tumours, rhabdoid tumours and Ewing sarcoma.